Recombinant Human ARRDC1 293 Cell Lysate

• Cat.No.: ARRDC1-8678HCL

Specification

• Description: Antigen standard for arrestin domain containing 1 (ARRDC1) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARRDC1 arrestin domain containing 1 [ Homo sapiens ]
• Official Symbol: ARRDC1
• Synonyms: RP11-48C7.5
• Gene ID: 92714
• mRNA Refseq: NM_152285.2
• Protein Refseq: NP_689498.1
• UniProt ID: Q8N5I2
• Chromosome Location: 9q34.3

Reviews

06/17/2022

I am confident that utilizing the ARRDC1 protein will empower me to uncover crucial insights into cellular mechanisms with precision.

01/16/2022

The ARRDC1 protein is an exceptional protein solution that exceeds expectations in terms of quality and suitability for my experimental requirements.

06/09/2016

Their expertise and guidance will undoubtedly prove valuable in overcoming hurdles and maximizing the potential of this protein in my research endeavors.

Q&As

Can targeting ARRDC1 be a potential therapeutic strategy for cardiovascular diseases?

Modulating the activity of ARRDC1 or its interaction with receptors could be a potential therapeutic strategy for cardiovascular diseases. By targeting ARRDC1, it may be possible to attenuate cardiac hypertrophy and prevent the progression of heart failure. However, further research is needed to fully understand the underlying mechanisms and determine the feasibility and efficacy of targeting ARRDC1 in the treatment of cardiovascular diseases.

Can ARRDC1 be targeted therapeutically?

Currently, there are no specific drugs or therapeutic agents that directly target ARRDC1. However, understanding the functional significance of ARRDC1 in disease processes may guide the development of novel therapeutic strategies in the future. Modulating ARRDC1 activity or its interaction with specific receptors could have therapeutic benefits in diseases where ARRDC1 dysregulation plays a role.

How does ARRDC1 regulate receptor signaling?

ARRDC1 can regulate receptor signaling through multiple mechanisms. It can directly bind to receptors and promote their internalization, leading to receptor desensitization. ARRDC1 can also recruit other proteins involved in receptor signaling pathways, thereby influencing downstream signaling events. Additionally, ARRDC1 has been shown to regulate the levels and stability of certain receptors by promoting their ubiquitination and targeting them for degradation.

Which receptors does ARRDC1 interact with?

ARRDC1 has been found to interact with a variety of receptors, including beta-adrenergic receptors, angiotensin receptors, platelet-derived growth factor receptors, and epidermal growth factor receptors. These interactions are important for the regulation of receptor signaling and downstream cellular responses.

Are there any diseases or conditions associated with ARRDC1 dysfunction?

There is emerging evidence to suggest that ARRDC1 dysregulation may be associated with various diseases and conditions. For example, altered expression levels of ARRDC1 have been observed in certain types of cancer, including lung and breast cancer. Furthermore, aberrant ARRDC1 signaling has been implicated in cardiac hypertrophy and heart failure.

Is ARRDC1 conserved across different species?

Yes, ARRDC1 is evolutionarily conserved across different species, including humans, mice, rats, and other organisms. This conservation suggests its importance in fundamental cellular processes and indicates potential functional significance across different organisms.

How is the expression of ARRDC1 regulated?

The expression of ARRDC1 can be regulated at both transcriptional and post-transcriptional levels. It has been reported that certain signaling pathways, such as the β-adrenergic signaling pathway, can upregulate ARRDC1 expression. Additionally, microRNAs have been identified that can bind to the ARRDC1 mRNA and regulate its stability, leading to changes in protein expression.